A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Inclusion Criteria:

• Disease progression on an irinotecan-based first-line chemotherapy regimen (ie FOLFIRIor CAPIRI [capecitabine + irinotecan], with or without bevacizumab)

• Age ≥ 18 years

• Life expectancy of ≥ 6 months

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 at study entry

• Agrees to adequate contraception during the study period and for 12 weeks after thelast dose of study medication

• Provided signed informed consent

Exclusion Criteria:

• Has received prior oxaliplatin-based chemotherapy for locally advanced unresectable ormetastatic Colorectal Cancer (CRC) (Prior oxaliplatin-based adjuvant chemotherapy isallowed if the last dose of oxaliplatin was administered > 12 months prior torandomization)

• Has documented and/or symptomatic brain or leptomeningeal metastases

• Has an ongoing or active infection, symptomatic or poorly controlled cardiacarrhythmia, psychiatric illness/social situations, or any other serious uncontrolledmedical disorders

• On chronic non-topical corticosteroid treatment. A participant discontinuing suchtreatment > 3 months prior to randomization is eligible

• Has uncontrolled or poorly controlled hypertension on a standard regimen ofantihypertensive therapy

• Has a concurrent active malignancy. A participant with previous history of malignancyis eligible, provided that he/she has been disease free for > 3 years

• If female, is pregnant (confirmed by serum beta human chorionic gonadotropin [βHCG]test) or lactating

• Has received a prior autologous or allogeneic organ or tissue transplantation

• Has undergone major surgery within 28 days prior to randomization

• Has had a serious nonhealing wound, ulcer, or bone fracture within 28 days prior torandomization

• Has an elective or planned major surgery to be performed during the course of thetrial

• Has a history of inflammatory bowel disease requiring pharmacological and/or surgicalintervention in the 12 months prior to randomization